A Phase II Study of Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide Before Stem Cell Transplantation in People with Recurrent or Persistent Diffuse Large B-Cell Lymphoma


Full Title

A Phase 2 Study of Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin and Etoposide (PolaR-ICE) as Initial Salvage Therapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma


A standard treatment for people with diffuse large B-cell lymphoma (DLBCL) that has come back or continued to grow despite therapy is a drug combination called RICE (rituximab, ifosfamide, carboplatin, and etoposide) given before autologous stem cell transplantation (ASCT). During ASCT, the patient receives their own healthy blood-forming cells (stem cells) to replace cells that have been destroyed by disease or anticancer drugs. Researchers think that adding polatuzumab vedotin to RICE may help these patients because all of these drugs slow the growth of cancer cells.

The purpose of this study is to assess the safety and effectiveness of adding polatuzumab vedotin to RICE in patients planning to have ASCT for recurrent or persistent DLBCL. All patients will receive polatuzumab vedotin with RICE before ASCT; if their cancer responds to this drug combination, they will receive polatuzumab vedotin alone after the transplant. All of the medications used in this study are given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following

  • Patients must have DLBCL that has come back or continued to grow despite one regimen of prior therapy.
  • Patients must be candidates for ASCT if their disease responds well to the treatment.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Matthew Matasar at 201-775-7428.





Disease Status

Relapsed or Refractory